Literature DB >> 22009041

Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.

Giovanna Cenini1, Amy L S Dowling, Tina L Beckett, Eugenio Barone, Cesare Mancuso, Michael Paul Murphy, Harry Levine, Ira T Lott, Frederick A Schmitt, D Allan Butterfield, Elizabeth Head.   

Abstract

Down syndrome (DS) is the most common genetic cause of intellectual disability in children, and the number of adults with DS reaching old age is increasing. By the age of 40 years, virtually all people with DS have sufficient neuropathology for a postmortem diagnosis of Alzheimer disease (AD). Trisomy 21 in DS leads to an overexpression of many proteins, of which at least two are involved in oxidative stress and AD: superoxide dismutase 1 (SOD1) and amyloid precursor protein (APP). In this study, we tested the hypothesis that DS brains with neuropathological hallmarks of AD have more oxidative and nitrosative stress than those with DS but without significant AD pathology, as compared with similarly aged-matched non-DS controls. The frontal cortex was examined in 70 autopsy cases (n=29 control and n=41 DS). By ELISA, we quantified soluble and insoluble Aβ40 and Aβ42, as well as oligomers. Oxidative and nitrosative stress levels (protein carbonyls, 4-hydroxy-2-trans-nonenal (HNE)-bound proteins, and 3-nitrotyrosine) were measured by slot-blot. We found that soluble and insoluble amyloid beta peptide (Aβ) and oligomers increase as a function of age in DS frontal cortex. Of the oxidative stress markers, HNE-bound proteins were increased overall in DS. Protein carbonyls were correlated with Aβ40 levels. These results suggest that oxidative damage, but not nitrosative stress, may contribute to the onset and progression of AD pathogenesis in DS. Conceivably, treatment with antioxidants may provide a point of intervention to slow pathological alterations in DS.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22009041      PMCID: PMC3260028          DOI: 10.1016/j.bbadis.2011.10.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  82 in total

1.  Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome.

Authors:  A Nunomura; G Perry; K Hirai; G Aliev; A Takeda; S Chiba; M A Smith
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

Review 2.  Oxidative stress and neural dysfunction in Down syndrome.

Authors:  R C Iannello; P J Crack; J B de Haan; I Kola
Journal:  J Neural Transm Suppl       Date:  1999

Review 3.  Genetic and host factors for dementia in Down's syndrome.

Authors:  Nicole Schupf; Gertrude H Sergievsky
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

4.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

Review 5.  Down's syndrome.

Authors:  Nancy J Roizen; David Patterson
Journal:  Lancet       Date:  2003-04-12       Impact factor: 79.321

Review 6.  4-Hydroxy-2-nonenal: a product and mediator of oxidative stress.

Authors:  Koji Uchida
Journal:  Prog Lipid Res       Date:  2003-07       Impact factor: 16.195

7.  In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1-42)

Authors:  S M Yatin; S Varadarajan; C D Link; D A Butterfield
Journal:  Neurobiol Aging       Date:  1999 May-Jun       Impact factor: 4.673

8.  Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid.

Authors:  Marzia Perluigi; Fabio di Domenico; Ada Fiorini; Annalisa Cocciolo; Alessandra Giorgi; Cesira Foppoli; D Allan Butterfield; Maurizio Giorlandino; Claudio Giorlandino; M Eugenia Schininà; Raffaella Coccia
Journal:  Proteomics Clin Appl       Date:  2011-02-24       Impact factor: 3.494

9.  Total numbers of neurons and glial cells in cortex and basal ganglia of aged brains with Down syndrome--a stereological study.

Authors:  Anna Schou Karlsen; Bente Pakkenberg
Journal:  Cereb Cortex       Date:  2011-03-22       Impact factor: 5.357

10.  Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage.

Authors:  Maria Manczak; Marcus J Calkins; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2011-03-31       Impact factor: 6.150

View more
  53 in total

1.  Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Cesare Mancuso; Eugenio Barone; Francesca Paolini; Andrea Arena; Carla Blarzino; Frederick A Schmitt; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 2.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

Review 3.  The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Authors:  Zi-Xuan Wang; Lan Tan; Jinyuan Liu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

4.  An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach.

Authors:  Giovanna Cenini; Ada Fiorini; Rukhsana Sultana; Marzia Perluigi; Jian Cai; Jon B Klein; Elizabeth Head; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-08-20       Impact factor: 7.376

Review 5.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

6.  Early life nutrient restriction impairs blood-brain metabolic profile and neurobehavior predisposing to Alzheimer's disease with aging.

Authors:  Masatoshi Tomi; Yuanzi Zhao; Shanthie Thamotharan; Bo-Chul Shin; Sherin U Devaskar
Journal:  Brain Res       Date:  2012-12-07       Impact factor: 3.252

Review 7.  Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.

Authors:  Antonella Tramutola; Fabio Di Domenico; Eugenio Barone; Andrea Arena; Alessandra Giorgi; Laura di Francesco; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Antioxid Redox Signal       Date:  2016-10-26       Impact factor: 8.401

Review 8.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

9.  Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.

Authors:  Lisi Flores-Aguilar; M Florencia Iulita; Olivia Kovecses; Maria D Torres; Sarah M Levi; Yian Zhang; Manor Askenazi; Thomas Wisniewski; Jorge Busciglio; A Claudio Cuello
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

Review 10.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.